文献速递心境障碍

人阿尔茨海默病脑源性可溶性Aβ的生物活性:病理生理与治疗机会

Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities.
PubMed 文献 · Mol Psychiatry · 2022-04-28

本文综述了从人阿尔茨海默病(AD)脑组织提取和表征具有生物活性的可溶性Aβ寡聚体(oAβ)的研究进展,以及其导致海马突触功能障碍的机制。人AD脑源性oAβ可损害海马长时程增强(LTP)并增强长时程抑制(LTD),可能通过直接干扰神经元NMDA受体、AMPA受体和代谢型谷氨酸受体(mGluRs),以及损害星形胶质细胞突触功能(包括谷氨酸摄取、D-丝氨酸释放和NMDA受体功能)发挥作用。这些结果可能提示针对oAβ中和与逆转谷氨酸介导兴奋性毒性的多靶点治疗策略。

要点

  • 人AD脑源性oAβ可损害海马LTP并增强LTD。
  • oAβ可能直接干扰神经元NMDA受体、AMPA受体和mGluRs。
  • oAβ也损害星形胶质细胞突触功能,包括谷氨酸摄取、D-丝氨酸释放和NMDA受体功能。

核心结论

  • 人AD脑源性oAβ具有损害海马突触可塑性的生物活性,可能通过多靶点机制参与AD病理生理。
  • 结果可能提示针对oAβ中和与逆转谷氨酸介导兴奋性毒性的多靶点治疗策略。

研究设计与样本

  • 综述,总结人AD脑组织oAβ的提取与表征及其导致海马突触功能障碍机制的研究进展。

主要发现

  • 人AD脑源性oAβ可损害海马LTP并增强LTD。
  • 许多研究提示oAβ可能直接干扰神经元NMDA受体、AMPA受体和代谢型谷氨酸受体(mGluRs)。
  • oAβ损害星形胶质细胞突触功能,包括谷氨酸摄取、D-丝氨酸释放和NMDA受体功能。
  • 综述还讨论了oAβ诱导的神经元过度兴奋。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The accumulation of amyloid-β protein (Aβ) plays an early role in the pathogenesis of Alzheimer's disease (AD). The precise mechanism of how Aβ accumulation leads to synaptic dysfunction and cognitive impairment remains unclear but is likely due to small soluble oligomers of Aβ (oAβ). Most studies have used chemical synthetic or cell-secreted Aβ oligomers to study their pathogenic mechanisms, but the Aβ derived from human AD brain tissue is less well characterized. Here we review updated knowledge on the extraction and characterization of bioactive human AD brain oAβ and the mechanisms by which they cause hippocampal synaptic dysfunction. Human AD brain-derived oAβ can impair hippocampal long-term potentiation (LTP) and enhance long-term depression (LTD). Many studies suggest that oAβ may directly disrupt neuronal NMDA receptors, AMPA receptors and metabotropic glutamate receptors (mGluRs). oAβ also impairs astrocytic synaptic functions, including glutamate uptake, D-serine release, and NMDA receptor function. We also discuss oAβ-induced neuronal hyperexcitation. These results may suggest a multi-target approach for the treatment of AD, including both oAβ neutralization and reversal of glutamate-mediated excitotoxicity.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Li S, Stern AM. Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities. Mol Psychiatry. 2022. PMID: 35484241. doi:10.1038/s41380-022-01589-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。